SG10201903210WA - Sunitinib Formulations and Methods for Use Thereof in Treatment of Ocular Disorders - Google Patents

Sunitinib Formulations and Methods for Use Thereof in Treatment of Ocular Disorders

Info

Publication number
SG10201903210WA
SG10201903210WA SG10201903210WA SG10201903210WA SG10201903210WA SG 10201903210W A SG10201903210W A SG 10201903210WA SG 10201903210W A SG10201903210W A SG 10201903210WA SG 10201903210W A SG10201903210W A SG 10201903210WA SG 10201903210W A SG10201903210W A SG 10201903210WA
Authority
SG
Singapore
Prior art keywords
sunitinib
methods
treatment
ocular disorders
analog
Prior art date
Application number
SG10201903210WA
Inventor
Jie Fu
Justin Hanes
Joshua Kays
Yun Yu
Ming Yang
Jeffrey Cleland
Walter Stark
Qingguo Xu
Jin Yang
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55069169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201903210W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of SG10201903210WA publication Critical patent/SG10201903210WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

SUNITINIB FORMULATIONS AND METHODS FOR USE THEREOF IN TREATMENT OF OCULAR DISORDERS Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more sustained 5 controlled release of sunitinib or its analog or a pharmaceutically acceptable salt thereof. Increased loading is achieved using an alkaline solvent system. The pharmaceutical compositions can be administered to treat or prevent a disease or disorder in or on the eye of a patient associated with vascularization, such as corneal neovascularization and acute macular degeneration. Upon administration, the sunitinib or its analog or salt is released over an 10 extended period of time at concentrations which are high enough to produce therapeutic benefit, but low enough to avoid unacceptable levels of cytotoxicity. No Figure to Accompany
SG10201903210WA 2014-12-15 2015-12-15 Sunitinib Formulations and Methods for Use Thereof in Treatment of Ocular Disorders SG10201903210WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462092118P 2014-12-15 2014-12-15
US201562139306P 2015-03-27 2015-03-27

Publications (1)

Publication Number Publication Date
SG10201903210WA true SG10201903210WA (en) 2019-05-30

Family

ID=55069169

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201903210WA SG10201903210WA (en) 2014-12-15 2015-12-15 Sunitinib Formulations and Methods for Use Thereof in Treatment of Ocular Disorders
SG11201704869VA SG11201704869VA (en) 2014-12-15 2015-12-15 Sunitinib formulations and methods for use thereof in treatment of ocular disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201704869VA SG11201704869VA (en) 2014-12-15 2015-12-15 Sunitinib formulations and methods for use thereof in treatment of ocular disorders

Country Status (19)

Country Link
US (4) US20170273901A1 (en)
EP (2) EP3233058A1 (en)
JP (3) JP6882186B2 (en)
KR (2) KR20170094793A (en)
CN (3) CN117398350A (en)
AU (2) AU2015362621B2 (en)
BR (1) BR112017012706A2 (en)
CA (1) CA2972075C (en)
CO (1) CO2017007003A2 (en)
EA (1) EA201791337A1 (en)
HK (1) HK1243942A1 (en)
IL (1) IL252943A0 (en)
MX (1) MX2017007873A (en)
NZ (1) NZ733130A (en)
PH (1) PH12017501097A1 (en)
RU (1) RU2729731C2 (en)
SG (2) SG10201903210WA (en)
WO (2) WO2016100380A1 (en)
ZA (1) ZA201703875B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6882186B2 (en) * 2014-12-15 2021-06-02 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ Methods for sunitinib preparations and their use in the treatment of eye disorders
BR112018005589A2 (en) 2015-09-22 2018-10-09 Graybug Vision Inc "Compound, pharmaceutically acceptable composition, and use of a compound"
BR112018009644A2 (en) 2015-11-12 2018-11-06 Graybug Vision Inc surface modified solid aggregate microparticles, injectable material, process for preparing surface modified solid aggregate microparticles, method for treating an eye disorder, and use of surface modified solid aggregate microparticles
RU2019133337A (en) 2017-03-23 2021-04-23 Грейбуг Вижн, Инк. DRUGS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
WO2018182527A1 (en) * 2017-03-30 2018-10-04 National University Of Singapore Method for treating inflammatory complications in eye diseases
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
CN111050754A (en) * 2017-07-17 2020-04-21 商福溪生技有限公司 Microparticle formulations for delivery of active agents
MX2020014160A (en) * 2018-06-25 2021-03-09 Titan Pharmaceuticals Inc Implants for release of lipophilic or amphiphilic pharmaceutical substances.
CN110946858A (en) * 2018-09-27 2020-04-03 中国科学院上海生命科学研究院 Use of indolinone derivatives for the treatment of obesity and related diseases
WO2020069353A1 (en) * 2018-09-27 2020-04-02 Graybug Vision, Inc. Compounds and compositions for ocular delivery
KR102322429B1 (en) * 2018-10-31 2021-11-08 주식회사 삼양홀딩스 Oral formulation containing sunitinib and the method for preparing the same
KR102308227B1 (en) * 2018-10-31 2021-10-05 주식회사 삼양홀딩스 Oral tablet composition containing sunitinib
TW202031292A (en) * 2018-11-15 2020-09-01 美商灰色視覺公司 Improved aggregated microparticles
JP7442914B2 (en) * 2019-04-30 2024-03-05 エルジー・ケム・リミテッド Caspase inhibitor prodrugs
US11471412B1 (en) * 2019-05-10 2022-10-18 University Of South Florida Nanoparticles and nanogel drug compositions for treatment of age-related macular degeneration
CN110833425B (en) * 2019-11-27 2022-12-30 佛山科学技术学院 Blood vessel holder for collecting blood of chick embryo
KR20240025990A (en) * 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 Amorphous sunitinib, preparation method thereof, and pharmaceutical composition containing amorphous sunitinib
KR20240028815A (en) 2022-08-25 2024-03-05 주식회사 스카이테라퓨틱스 A molecule aggregates composite of active pharmaceutical ingredient and a pharmaceutical composition comprising the same
WO2024095026A1 (en) 2022-11-04 2024-05-10 Semmelweis Egyetem In vivo targeting of therapeutic molecules to the retina via the optical system of the eye

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929401A (en) 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
GB929406A (en) 1958-12-22 1963-06-19 Upjohn Co A process for the production of encapsulated material
GB969808A (en) 1962-06-08 1964-09-16 Boots Pure Drug Co Ltd Anthelmintic compositions and compounds
IT1148784B (en) 1980-04-09 1986-12-03 Eurand Spa PROCEDURE FOR THE PREPARATION OF MICRO CAPSULES IN A LIQUID VEHICLE
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4991920A (en) 1988-12-27 1991-02-12 Andrzej Peczalski Optical converter
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5441722A (en) 1994-02-18 1995-08-15 Merck & Co., Inc. Short synthesis of 5,6-dihydro-(S)-4-(ethylamino)-(S)-6-[C3 H3 ]-4[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide and related non radioactive compounds
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
WO1996020698A2 (en) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6841617B2 (en) 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
EP1137373A4 (en) 1998-12-04 2004-05-19 Chandrashekhar P Pathak Biocompatible crosslinked polymers
US20040258763A1 (en) 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6706289B2 (en) 2000-10-31 2004-03-16 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7060299B2 (en) 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
US20070122487A1 (en) * 2003-03-19 2007-05-31 University Of Kentucky Research Foundation (Poly(acryloyl-hydroxyethyl starch)-plga composition microspheres
GB0307011D0 (en) 2003-03-27 2003-04-30 Regentec Ltd Porous matrix
DE602004016995D1 (en) 2003-06-26 2008-11-20 Control Delivery Sys Inc IN-SITU GELIEREN MEDZIMITTELABGABESYSTEM
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
EP1713514B1 (en) 2004-01-28 2021-11-24 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
ES2246694B1 (en) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. PEGILATED NANOPARTICLES.
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
US20070149593A1 (en) 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US8663674B2 (en) 2006-01-13 2014-03-04 Surmodics, Inc. Microparticle containing matrices for drug delivery
US20080166411A1 (en) 2006-04-10 2008-07-10 Pfizer Inc Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
EP2061433B1 (en) 2006-09-08 2011-02-16 Johns Hopkins University Compositions for enhancing transport through mucus
GB0619869D0 (en) 2006-10-07 2006-11-15 Regentec Ltd Porous particles
ES2421206T3 (en) 2006-11-09 2013-08-29 Alcon Research, Ltd. Water-insoluble polymer matrix for drug delivery
GB0701896D0 (en) 2007-02-01 2007-03-14 Regentec Ltd Composition
JP2010519183A (en) 2007-02-06 2010-06-03 インセプト エルエルシー Polymerization using protein precipitation for elution of physiological solutions
WO2008157614A2 (en) 2007-06-21 2008-12-24 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
CN101081206A (en) * 2007-06-29 2007-12-05 济南康泉医药科技有限公司 Anti-cancer medicine composition containing tyrosine kinase restraining agent
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
EP2207577B1 (en) 2007-10-26 2015-01-14 National Institute Of Immunology Biodegradable polymer scaffold and process for preparation thereof
US20090203709A1 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
EP2255788B1 (en) 2008-02-29 2015-07-22 Nagoya Industrial Science Research Institute Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye
CN101336890A (en) 2008-05-30 2009-01-07 济南基福医药科技有限公司 Anticancer sustained-release gel injection
WO2010017541A2 (en) * 2008-08-08 2010-02-11 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
TW201019963A (en) 2008-09-10 2010-06-01 Abbott Lab Polyethylene glycol lipid conjugates and uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
CA2752419A1 (en) 2009-01-12 2010-07-15 Hadasit Medical Research Services & Development Limited Tissue regeneration membrane
EP2391419B1 (en) 2009-01-29 2019-06-12 ForSight Vision4, Inc. Posterior segment drug delivery
WO2010091187A2 (en) 2009-02-04 2010-08-12 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
JP5890182B2 (en) 2009-02-12 2016-03-22 インセプト エルエルシー Drug delivery with hydrogel plugs
CA2753690A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
GB0903810D0 (en) 2009-03-05 2009-04-22 Regentec Ltd Delivery system
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
CA3042067C (en) 2009-12-15 2022-10-18 Incept, Llc Implants and biodegradable fiducial markers
WO2011106702A2 (en) * 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2011109384A2 (en) 2010-03-02 2011-09-09 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
WO2011119777A2 (en) * 2010-03-23 2011-09-29 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
CA3054532C (en) 2010-11-05 2022-07-12 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US9382229B2 (en) 2011-02-15 2016-07-05 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
CN103127096B (en) * 2011-12-02 2015-11-25 杨子娇 The Benzazole compounds that pyrrole radicals replaces is in the application for the treatment of glaucoma
KR20190090048A (en) 2011-12-05 2019-07-31 인셉트, 엘엘씨 Medical organogel processes and compositions
RU2631599C2 (en) 2011-12-14 2017-09-25 Дзе Джонс Хопкинс Юниверсити Nanoparticles easily penetrating into mucosa or inducing less inflammation
CN104936620B (en) 2012-01-19 2019-08-09 约翰霍普金斯大学 Enhance the nanoparticle composite of transmucosal
AU2013232297B2 (en) 2012-03-16 2016-01-14 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
WO2013138346A1 (en) 2012-03-16 2013-09-19 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
EP2844223A1 (en) * 2012-05-03 2015-03-11 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
EP2849728A1 (en) 2012-05-04 2015-03-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
EP2852388A4 (en) * 2012-05-23 2016-01-13 Univ Johns Hopkins Compounds and methods of use thereof for treating neurodegenerative disorders
JP2017512748A (en) * 2012-06-25 2017-05-25 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ Ophthalmic topical pharmaceutical composition containing sunitinib
AU2013315125B2 (en) * 2012-09-17 2018-07-26 Pfizer Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
CN103848985B (en) * 2012-11-30 2018-03-02 杨子剑 Noval chemical compound and preparation method and purposes containing Sutent analog structure
EP2981248B1 (en) 2013-04-01 2020-09-02 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
CN104208715B (en) 2013-05-31 2016-12-28 天津键凯科技有限公司 There is the medicine bioactive low molecular poly drug conjugates of raising
JP5698882B1 (en) 2013-06-18 2015-04-08 昭和電工株式会社 Capacitor anode body and manufacturing method thereof
US10646027B2 (en) 2013-08-29 2020-05-12 Sayeeda Mazed Multifunctional personal care devices/apparatuses and compositions for hair or skin
US20160310417A1 (en) 2013-12-20 2016-10-27 Emory University Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents
KR101564401B1 (en) 2014-04-10 2015-11-02 한국화학연구원 Process for the preparation of brinzolamide
KR20170046146A (en) 2014-08-13 2017-04-28 더 존스 홉킨스 유니버시티 Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization
WO2016060925A1 (en) 2014-10-16 2016-04-21 Incept, Llc Ocular gels or hydrogels and microinjectors
WO2016065245A1 (en) 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
JP7092502B2 (en) 2014-12-10 2022-06-28 インセプト・リミテッド・ライアビリティ・カンパニー Hydrogel drug delivery implant
JP6882186B2 (en) * 2014-12-15 2021-06-02 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ Methods for sunitinib preparations and their use in the treatment of eye disorders
JP6479485B2 (en) 2015-01-15 2019-03-06 大内新興化学工業株式会社 Nanoparticle preparation for treatment of eye diseases
US20180008718A1 (en) 2015-01-20 2018-01-11 The Johns Hopkins University Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure
MX2017014084A (en) 2015-05-05 2018-06-20 Psivida Inc Injectable depot formulations.
EP4279064A3 (en) 2015-05-12 2024-02-28 Incept, LLC Drug delivery from hydrogels
JP2018525078A (en) 2015-07-22 2018-09-06 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ Coated punctum plug
JP2018536484A (en) 2015-11-25 2018-12-13 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ Shape-changing drug delivery device and method

Also Published As

Publication number Publication date
SG11201704869VA (en) 2017-07-28
US20170360750A1 (en) 2017-12-21
JP6882186B2 (en) 2021-06-02
JP2017537985A (en) 2017-12-21
RU2017123358A3 (en) 2019-08-30
US20170273901A1 (en) 2017-09-28
IL252943A0 (en) 2017-08-31
NZ733130A (en) 2018-09-28
PH12017501097A1 (en) 2017-11-27
US20210251959A1 (en) 2021-08-19
MX2017007873A (en) 2017-11-06
EP3233056A1 (en) 2017-10-25
CA2972075C (en) 2020-07-14
BR112017012706A2 (en) 2018-03-13
US20200147044A1 (en) 2020-05-14
CN117398350A (en) 2024-01-16
KR20170094794A (en) 2017-08-21
AU2015362621B2 (en) 2019-01-17
JP2018500394A (en) 2018-01-11
US10525034B2 (en) 2020-01-07
RU2017123358A (en) 2019-01-17
JP6847848B2 (en) 2021-03-24
AU2015362621A1 (en) 2017-07-13
CN107205940A (en) 2017-09-26
AU2019202037B2 (en) 2021-01-21
CA2972075A1 (en) 2016-06-23
WO2016100392A1 (en) 2016-06-23
ZA201703875B (en) 2019-11-27
KR20170094793A (en) 2017-08-21
EP3233056B1 (en) 2023-11-15
AU2019202037A1 (en) 2019-04-18
EA201791337A1 (en) 2017-11-30
WO2016100380A1 (en) 2016-06-23
CN107278151A (en) 2017-10-20
US11013719B2 (en) 2021-05-25
CO2017007003A2 (en) 2017-10-20
JP2021119183A (en) 2021-08-12
RU2729731C2 (en) 2020-08-11
HK1243942A1 (en) 2018-07-27
EP3233058A1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
PH12017501097A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
EA201491711A1 (en) CONJUGATES OF NONLINEAR MULTIPLACE COPOLYMER WITH A MEDICINE FOR DELIVERY OF ACTIVE AGENTS
MX2016014634A (en) Compounds for treating ophthalmic diseases and disorders.
WO2015095772A3 (en) Formulations and methods for targeted ocular delivery of therapeutic agents
PH12019500423A1 (en) Pharmaceutical composition
JP2017537985A5 (en)
EP4324454A3 (en) Cross-linking agents and associated methods
AR088585A1 (en) A MEDICINAL PRODUCT TO TREAT THE PREVIOUS EYE DISEASE
MX2016011333A (en) Drug delivery systems and methods for treatment of bladder cancer with gemcitabine.
MY189110A (en) Fast acting orally disintegrating film
AR079683A1 (en) OPTICAL TOPIC FORMULATION OF PEPTIDES
WO2015048188A8 (en) Modified fibroblast growth factors for the treatment of ocular disorders
MX2017005163A (en) Onapristone extended-release compositions and methods.
CL2020001426A1 (en) Topical ophthalmic composition comprising dobesilic acid to treat diseases of the posterior segment of the eye.
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
FI3352735T3 (en) Sustained release olanzapine formulations
MX2022002306A (en) Methods of treatment of ocular conditions with a sustained drug delivery implant.
RU2010154623A (en) Derivatives of 1-aminoalkylcyclohexane for the treatment of sleep disorders
MX2016014740A (en) A method for treating movement disorders with befiradol.
AR099872A1 (en) PROGESTERONE FORMULATIONS
MX2016006375A (en) A combination of dosage units for use in the treatment of pre-term labour condition.
PH12017501796A1 (en) Dry eye therapeutic agent comprising nandrolone or ester thereof or methenolone or ester thereof as an active ingredient
Ryoo Eye disorders following an accidental intraocular injection: case report
Kwon et al. Novel Glaucoma Treatment using Osmotic Pump in Dogs
JP2016515616A5 (en)